Nasdaq closing cross sets record during Russell index rebalancing
Get Alerts NDAQ Hot Sheet
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 1.2%
Revenue Growth %: +9.2%
Join SI Premium – FREE
Nasdaq, Inc. (NASDAQ: NDAQ) reported that its Closing Cross processed a record 4,594,880,616 shares valued at $334.027 billion during the June 2026 Russell US Indexes reconstitution, executed in 1.630 seconds.
The figures surpass the previous record set during the 2025 Russell reconstitution, when 2,506,428,416 shares totaling $102.455 billion were executed in 0.871 seconds.
The Russell US Indexes — which include the Russell 1000, Russell 2000, and Russell 3000 — undergo semi-annual reconstitution to reflect changes in market capitalization, sector composition, and investment style among publicly traded U.S. companies. This marks the 23rd year the Nasdaq Closing Cross has been used to calculate the Russell reconstitution.
"Today's record shows the infrastructure underpinning the US market close continuing to scale with the market it serves, delivering a single, transparent closing price across record volume in under a second," said Kevin Kennedy, EVP of North American Markets at Nasdaq.
Fiona Bassett, CEO of FTSE Russell, said the record notional volume "underscores the continued trust the investment community places in our transparent and rules-based process."
The newly reconstituted index membership is set to take effect when markets open on June 29, 2026. Approximately $10.6 trillion in assets are benchmarked to or invested in products based on the Russell US Indexes.
According to the press release, since the Nasdaq Closing Cross began calculating the Russell reconstitution, latency has been reduced by more than 85%, while trade volume has grown more than 550% and notional volume has grown more than 1,500%.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Alphabet Sees FY26 Capex $195B To $205B, Saw $180B To $190B
- Five Below reports cybersecurity breach via social engineering
- Dexcom selected as first participant in FDA's TEMPO pilot
Create E-mail Alert Related Categories
Corporate NewsRelated Entities
Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share